Home › Companies › VERA

Vera Therapeutics, Inc.

VERA Rare disease Lead: NDA Submitted 4 Biotech Distilled articles ↓

Infectious Disease Renal Protein Small Molecule

Most recent annual filing: 2026-02-15

Pipeline (8 active programs)

atacicept

Protein Target: BAFF, APRIL, TACI

IgA Nephropathy NDA Submitted subcutaneous Ares Trading S.A.
Primary Membranous Nephropathy Phase 2 subcutaneous Ares Trading S.A.
Focal Segmental Glomerulosclerosis Phase 2 subcutaneous Ares Trading S.A.
Minimal Change Disease Phase 2 subcutaneous Ares Trading S.A.
Membranous Nephropathy Phase 2

MAU868

Protein Target: BKV VP1, BK virus

BK Virus Infection Phase 2 intravenous Novartis

VT-109

Protein Target: BAFF, APRIL

Undisclosed indication Preclinical Stanford
Undisclosed indication Preclinical

Biotech Distilled coverage (4)

2026-03-07 UPDATE: Vera Therapeutics (VERA) - VERA Adds an M&A Heavyweight to the Board 🔒 Paid
2026-02-28 UPDATE: Vera Therapeutics (VERA) - FY25 Wrap-Up 🔒 Paid
2026-01-07 UPDATE: Vera Therapeutics (VERA) Hits the Accelerator – FDA Grants Priority Review 🔒 Paid
2025-12-16 Vera Therapeutics (VERA): Scientific Due Diligence for Atacicept and Pipeline 🔒 Paid

Articles open on Substack. Some deep dives are subscriber-only.